Copy Number Variation Analysis in Familial BRCA1/2-Negative Finnish Breast and Ovarian Cancer

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Kuusisto, Kirsi M ^a   Akinrinade, Oyediran ^a   Vihinen, Mauno ^b   Kankuri Tammilehto, Minna ^c   Laasanen, Satu Leena ^d   Schleutker, Johanna ^a,e  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b LUND UNIVERSITY   (Sweden)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A3; EPHRIN RECEPTOR A3 TYROSINE KINASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; CSMD1 GENE; EPHA3 GENE; ERBB4 GENE; ERVV 2 GENE; ETHNIC GROUP; EXON; FAMILIAL CANCER; FEMALE; FINLAND; FINNISH; GENE; GENE DELETION; GENE DUPLICATION; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEREDITARY BREAST AND OVARIAN CANCER; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; NBR1 GENE; NBR2 GENE; NOMENCLATURE; ONCOGENE; ONCOGENE BRCA2; OVARY CANCER; POLYMERASE CHAIN REACTION; POPULATION GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CASE-CONTROL STUDIES; DNA COPY NUMBER VARIATIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FINLAND; GENE DELETION; GENE DUPLICATION; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GERM-LINE MUTATION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMANS; MIDDLE AGED; PEDIGREE; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84881515732     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071802     Document Type: Article

References (41)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71.
2. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, et al. (1996) The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12: 333-337.
3. Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, et al. (1997) Low proportion of BRCA1 and BRCA2 mutations in finnish breast cancer families: Evidence for additional susceptibility genes. Hum Mol Genet 6: 2309-2315.
4. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, et al. (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71: 432-438.
5. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, et al. (2007) A recurrent mutation in PALB2 in finnish cancer families. Nature 446: 316-319.
6. Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, et al. (2011) RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 20: 3278-3288.
7. Solyom S, Aressy B, Pylkas K, Patterson-Fortin J, Hartikainen JM, et al. (2012) Breast cancer-associated abraxas mutation disrupts nuclear localization and DNA damage response functions. Sci Transl Med 4: 122ra23.
8. Stankiewicz P, Lupski JR, (2010) Structural variation in the human genome and its role in disease. Annu Rev Med 61: 437-455.
9. Feuk L, Carson AR, Scherer SW, (2006) Structural variation in the human genome. Nat Rev Genet 7: 85-97.
10. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, et al. (2007) Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315: 848-853.
11. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, et al. (2008) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320: 539-543.
12. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, et al. (2010) Functional impact of global rare copy number variation in autism spectrum disorders. Nature 466: 368-372.
13. Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, et al. (2009) Copy number variation at 1q21.1 associated with neuroblastoma. Nature 459: 987-991.
14. Liu W, Sun J, Li G, Zhu Y, Zhang S, et al. (2009) Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer. Cancer Res 69: 2176-2179.
15. Venkatachalam R, Verwiel ET, Kamping EJ, Hoenselaar E, Gorgens H, et al. (2011) Identification of candidate predisposing copy number variants in familial and early-onset colorectal cancer patients. Int J Cancer 129: 1635-1642.
16. Krepischi AC, Achatz MI, Santos EM, Costa SS, Lisboa BC, et al. (2012) Germline DNA copy number variation in familial and early-onset breast cancer. Breast Cancer Res 14: R24.
17. Pylkas K, Vuorela M, Otsukka M, Kallioniemi A, Jukkola-Vuorinen A, et al. (2012) Rare copy number variants observed in hereditary breast cancer cases disrupt genes in estrogen signaling and TP53 tumor suppression network. PLoS Genet 8: e1002734.
18. Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL, (2011) Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res 13: R20.
19. Wang K, Li M, Hadley D, Liu R, Glessner J, et al. (2007) PennCNV: An integrated hidden markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 17: 1665-1674.
20. Colella S, Yau C, Taylor JM, Mirza G, Butler H, et al. (2007) QuantiSNP: An objective bayes hidden-markov model to detect and accurately map copy number variation using SNP genotyping data. Nucleic Acids Res 35: 2013-2025.
21. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
22. Meyer D, Zeileis A, Hornik K (2012) Vcd: Visualizing categorical data. R package version 1.2-13.
23. Zhang B, Kirov S, Snoddy J, (2005) WebGestalt: An integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33: W741-8.
24. Pasquale EB, (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133: 38-52.
25. Pasquale EB, (2010) Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat Rev Cancer 10: 165-180.
26. Xi HQ, Wu XS, Wei B, Chen L (2012) Aberrant expression of EphA3 in gastric carcinoma: Correlation with tumor angiogenesis and survival. J Gastroenterol.
27. Xi HQ, Zhao P, (2011) Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol 64: 498-503.
28. Guan M, Liu L, Zhao X, Wu Q, Yu B, et al. (2011) Copy number variations of EphA3 are associated with multiple types of hematologic malignancies. Clin Lymphoma Myeloma Leuk 11: 50-53.
29. Kleinjan DA, van Heyningen V, (2005) Long-range control of gene expression: Emerging mechanisms and disruption in disease. Am J Hum Genet 76: 8-32.
30. Li J, Ye L, Mansel RE, Jiang WG, (2011) Potential prognostic value of repulsive guidance molecules in breast cancer. Anticancer Res 31: 1703-1711.
31. Jain AN, Chin K, Borresen-Dale AL, Erikstein BK, Eynstein Lonning P, et al. (2001) Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci U S A 98: 7952-7957.
32. Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, et al. (2009) Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther 8: 907-916.
33. Kamal M, Shaaban AM, Zhang L, Walker C, Gray S, et al. (2010) Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma. Breast Cancer Res Treat 121: 555-563.
34. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, et al. (2008) Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 13: 259-268.
35. Hynes NE, Lane HA, (2005) ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
36. Woodward AM, Davis TA, Silva AG, Kirk JA, Leary JA, et al. (2005) Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families. J Med Genet 42: e31.
37. Pylkas K, Erkko H, Nikkila J, Solyom S, Winqvist R, (2008) Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in finnish breast and ovarian cancer families. BMC Cancer 8: 146.
38. Garcia-Casado Z, Romero I, Fernandez-Serra A, Rubio L, Llopis F, et al. (2011) A de novo complete BRCA1 gene deletion identified in a spanish woman with early bilateral breast cancer. BMC Med Genet 12: 134.
39. Gad S, Bieche I, Barrois M, Casilli F, Pages-Berhouet S, et al. (2003) Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a french breast-ovarian cancer family. Hum Mutat 21: 654.
40. Ruprecht K, Mayer J, Sauter M, Roemer K, Mueller-Lantzsch N, (2008) Endogenous retroviruses and cancer. Cell Mol Life Sci 65: 3366-3382.
41. Nexo BA, Vogel U, Olsen A, Nyegaard M, Bukowy Z, et al. (2008) Linkage disequilibrium mapping of a breast cancer susceptibility locus near RAI/PPP1R13L/iASPP. BMC Med Genet 9: 56-2350-9-56.